There won't be any unicorns with their current strategy. They...

There won't be any unicorns with their current strategy. They have been fairly transparent with their current strategy in terms of the market they are targeting and also the size of that market. They are targeting many generic drugs - the market size varies.

The strategy has only been partially executed:
- FDA approval for the testosterone generic - TICK
- Sales figures for the testosterone generic - PENDING
- Further FDA approvals - PENDING

I would say their strategy is successful once they have a steady flow of revenues from generics and a rolling pipeline of generics with the FDA.

Also note, they have 2 non-generics in the market which have been growing steadily.